Adding TNF to chemoradiotherapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding a drug called TNF (a protein that may help the immune system fight cancer) to the usual chemoradiotherapy (chemotherapy plus radiation) improves outcomes for people with locally advanced nasopharyngeal cancer. If you join, you may receive the standard treatment with or without TNF, and the study will monitor how well the cancer responds and any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have nasopharyngeal cancer (a type of cancer at the back of your nose/throat) that has not spread to other organs.
- If your cancer is stage III, you need a high level of EBV DNA in your blood (a marker some doctors use).
- You must not have had radiation or chemotherapy for this cancer before.
- You should be generally active and able to care for yourself (a score of at least 70 on a standard scale, with some flexibility).
- You must have a tumor that can be measured by scans and have acceptable kidney, liver, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial tests combining induction chemotherapy and immunotherapy with radiation, with or without additional chemotherapy, for patients with advanced nasopharyngeal cancer (throat cancer). It aims to see if adding chemotherapy during radiation improves outcomes compared to not having it.
This trial tests whether adding chemotherapy before the usual radiation and chemotherapy treatment can improve outcomes for people with a certain type of nasopharyngeal cancer that has higher risk features. It aims to see if the extra treatment helps control the cancer better.
This study tests nituzumab (a targeted antibody) added to standard induction chemotherapy versus placebo plus chemotherapy. It aims to improve tumor control and safety for people with locally advanced nasopharyngeal (throat) cancer.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial compares two treatment options for people with nasopharyngeal cancer that did not respond well to initial chemotherapy. One option is to switch to a different chemotherapy regimen, the other is to go straight to radiation therapy. The study aims to see which approach is more effective in this situation.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.